BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'

Reuters

Jun 24, 2025

BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'

** Shares of drug developer Septerna SEPN.O rise 1.8% to $10.66

** Brokerage H.C. Wainwright initiates coverage with "buy" rating, sets PT at $26

** SEPN's thyroid-stimulating hormone receptor $(TSHR)$ NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage

** Novo Nordisk NOVOb.CO in May struck a $2.2 billion collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases

** Brokerage believes the structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk

** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-targeted candidates - Wainwright

** Up to last close, stock down 54.3% YTD

(Reporting by Juby Babu in Mexico City)

((Juby.Babu@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545468544"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545468544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545468544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545468544","market":"us","top_or_hot":-1,"title":"BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'</title></head><body><p>** Shares of drug developer Septerna <span>SEPN.O</span> rise 1.8% to $10.66</p><p>** Brokerage H.C. Wainwright initiates coverage with \"buy\" rating, sets PT at $26</p><p>** SEPN's thyroid-stimulating hormone receptor <a href=\"https://laohu8.com/S/TSHR\">$(TSHR)$</a> NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage</p><p>** Novo Nordisk <span>NOVOb.CO</span> in May struck a <span>$2.2 billion</span> collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases</p><p>** <span>Brokerage believes the</span> structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk </p><p>** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-targeted candidates - Wainwright</p><p>** Up to last close, stock down 54.3% YTD</p><p>(Reporting by Juby Babu in Mexico City)</p><p>((Juby.Babu@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 00:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'</title></head><body><p>** Shares of drug developer Septerna <span>SEPN.O</span> rise 1.8% to $10.66</p><p>** Brokerage H.C. Wainwright initiates coverage with \"buy\" rating, sets PT at $26</p><p>** SEPN's thyroid-stimulating hormone receptor <a href=\"https://laohu8.com/S/TSHR\">$(TSHR)$</a> NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage</p><p>** Novo Nordisk <span>NOVOb.CO</span> in May struck a <span>$2.2 billion</span> collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases</p><p>** <span>Brokerage believes the</span> structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk </p><p>** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-targeted candidates - Wainwright</p><p>** Up to last close, stock down 54.3% YTD</p><p>(Reporting by Juby Babu in Mexico City)</p><p>((Juby.Babu@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nL4N3SQ16V:1","article_id":"2545468544","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545468544","pubTimestamp":1750694667,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'** Shares of drug developer Septerna SEPN.O rise 1.8% to $10.66** Brokerage H.C. Wainwright initiates coverage with \"buy\" rating, sets PT at $26** SEPN's thyroid-stimulating hormone receptor  NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage** Novo Nordisk NOVOb.CO in May struck a $2.2 billion collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases** Brokerage believes the structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk ** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-tar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SEPN":"Septerna, Inc."},"translate_title":"H.C.之后的嗡嗡声。温赖特以“买入”开始报道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SEPN":0.9},"content_text":"BUZZ-Septerna up after H.C. Wainwright starts coverage with 'buy'** Shares of drug developer Septerna SEPN.O rise 1.8% to $10.66** Brokerage H.C. Wainwright initiates coverage with \"buy\" rating, sets PT at $26** SEPN's thyroid-stimulating hormone receptor $(TSHR)$ NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage** Novo Nordisk NOVOb.CO in May struck a $2.2 billion collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases** Brokerage believes the structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk ** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-targeted candidates - Wainwright** Up to last close, stock down 54.3% YTD(Reporting by Juby Babu in Mexico City)((Juby.Babu@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}